RE:RE:RE:RE:RE:RE:RE:RE:This is it...It is my belief that the potential impact on pharma firms now involved in cancer therapy is one of factors in the FDA's thinking as Ruvidar/PDTworks its way through the approval process and that this possible concern is making for a more intense scrutiny of Theralase's breakthrough treatment.
The potential impact this treatment appears to be one that it could unseat nearly all of the currently approved and employed practices - it is likely to be very disruptive, if in fact the long term results establish the promise on a wider scope, the treatment will be a colossal game changer.
Medicine has seen such happenings in many forms for decades.
Therelase should be under harsher scrutiny because iof this and because of the nature of its neophyte construct in the pharma industry.
If so, no wonder it is taking so long.
All solely my opinion.